Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP EBITDA Margin

EBITDA as a percentage of revenue.

Coeptis Therapeutics, Inc.NASDAQ: COEP

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -3081.3%

EBITDA Margin was -3081.3% in Q1 FY2026, up 1760.4 pp from a year earlier. On a trailing-twelve-month basis it was -769.0%, up 15034.6 pp year over year.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 20.0% for the fiscal year ending Dec 2026, up from -763.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-3081.3%-2979.6 pp QoQ
Last fiscal yearDec 2025
-763.9%— YoY
LTMMar 2026
-769.0%+15034.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1760.4 pp+1993.9 pp+233.6 pp
1 year—+783.9 pp—
3 years———
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-763.9%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 EBITDA Margin of -769.0% is the 4th highest of the 6 companies compared; the peer median is -97.9%.
  • Its year-over-year change of +15034.6 pp is the highest of 5, against a peer median of +166.4 pp.
COEP Competitors Peer median
EBITDA Margin for COEP and competitors
Company Period LTM level YoY 3-year change
IPSCCentury Therapeutics, Inc.FY20253.2% +1695.0 pp+2334.4 pp
CUECue Biopharma, Inc.LTM Mar 2026-48.4% +416.8 pp+3974.4 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026-97.9% -84.1 pp-13.9 pp
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-769.0% +15034.6 pp—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-1017.5% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18634.1% -28166.9 pp—
EQEquillium, Inc.FY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
TELOTelomir Pharmaceuticals, Inc. Common StockFY2025— ——
Peer median (excluding COEP) -97.9%+166.4 pp+2334.4 pp

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75K0001.36M
Cost of Revenue0000180.63K
Gross Profit75K0001.18M
Gross Margin100.0%———86.7%
Research & Development020.89K6.67M2.33M1.28M
Selling, General & Admin14.12M34.18M13.82M6.72M11.95M
Operating Expenses14.12M34.2M21.49M10.05M14.23M
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
EBITDA(12.81M)(36.35M)(20.12M)(9.38M)(10.41M)
EBITDA Margin-17086.3%———-763.9%
Operating Income(14.05M)(34.2M)(21.49M)(10.05M)(13.04M)
Operating Margin-18727.9%———-956.9%
Interest Income0000116.5K
Interest Expense187.13K218.41K107.69K396.12K642.38K
Other Income / Expenses596.65K(3.38M)224.59K(822.92K)766.31K
Income Before Tax(13.45M)(37.57M)(21.27M)(10.88M)(12.28M)
Pre-Tax Margin-17932.4%———-900.7%
Income Tax Expense00000
Net Income(13.45M)(37.57M)(21.27M)(10.68M)(11.92M)
Net Margin-17932.4%———-874.3%
EPS (Basic)(13.16)(2.87)(0.83)(5.65)(2.81)
EPS (Diluted)(13.16)(2.87)(0.83)(5.65)(2.81)
Weighted Avg Shares1.02M14.3M25.69M1.93M4.23M
Weighted Avg Shares (Diluted)1.02M14.3M25.69M1.93M4.23M

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.